Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugssanford health plan Stelara biosimilars Coverage U…
    Ask Trek AI about this page
    Modifiedsanford health planPolicy N/A

    Stelara biosimilars formulary placement and related provider guidance

    Customize your policy alerts

    Sign up for all sanford health plan policy alerts

    Know when sanford health plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governance of Sanford Health Plan's formulary changes for Stelara and newly preferred biosimilars, who this affects (providers prescribing Stelara or its biosimilars and Sanford members), and related portal/authorization guidance for providers.

    Policy Summary
    Payersanford health plan
    PolicyStelara biosimilars formulary placement and related provider guidance
    Policy CodePolicy N/A
    Change TypeFormulary additions and tiering update
    Effective DateApr 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for new patients starting Stelara or biosimilars and document case-specific justification for exceptions to remain on originator Stelara.
    SourceLink
    POLICY UPDATE CHANGES

    Three biosimilars to Stelara (Selarsdi, Wezlana, Yesintek) were added to the Sanford Health Plan formulary as preferred options.

    No prior authorization is required for patients currently treated with Stelara to be switched to one of the biosimilars; exceptions to remain on Stelara require prior authorization.

    Guidance encouraging providers to begin new patients on biosimilars and to discuss switching current patients to biosimilars.

    3Stelara biosimilars added to formulary
    2025-04-01Effective date for lowest cost-share

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    highest-costStelara placement if patient stays on originator
    30 daysRequired Initiation follow-up
    210Minimum days for C&M

    Coverage Criteria and Policy Rules

    Stelara and Biosimilar Coverage Rules

    Covered when plan-preference and authorization rules are followed.

    Formulary placement and initiation: Biosimilars Selarsdi, Wezlana, and Yesintek are preferred formulary options and should be used when initiating therapy; biosimilars will be the lowest cost-share effective April 1, 2025.

    New patients require prior authorization as noted by the plan.

    Switching current patients: Current patients on Stelara may be switched to a biosimilar without prior authorization, except where the provider documents case-specific reasons to remain on Stelara.

    Exceptions to remain on Stelara require prior authorization and case-by-case review.

    Interchangeability: Wezlana is designated as an interchangeable biosimilar; pharmacists may not require a new prescription to dispense Wezlana where substitution laws allow.

    Providers should be aware of interchangeability status when counseling patients.

    ADD-E: Initiation and Continuation & Maintenance

    Coverage/performance expectations for the ADD-E HEDIS measure.

    ADD-E Initiation and C&M criteria: Member is ages 6-12 AND has a new prescription dispensed for ADHD medication AND had a follow-up visit with a prescribing practitioner within 30 days of medication start (Initiation Phase) AND for Continuation and Maintenance: member remained on medication >=210 days AND had at least two additional follow-up visits with any practitioner within 270 days after the Initiation Phase ended.age 6-12; 30 days; >=210 days; 270 days

    One visit between days 31 and 300 may be an e-visit or virtual check-in. Schedule visits at approximately 30, 60 and 180 days; consider an initial two-week supply and follow-up prescriptions for 30 days.

    APP/APM: Psychological care and metabolic monitoring

    Expectations for antipsychotic prescribing quality measures (APP and APM).

    APP and APM expectations: APP: children/adolescents prescribed antipsychotics should receive first-line psychological care (therapy/behavioral interventions) when appropriate. APM: children/adolescents on antipsychotics should receive routine metabolic monitoring (height, weight, blood pressure, glucose, lipids).regular metabolic screenings per clinical judgement

    Use EHR reminders and coordinate care with pediatricians, dietitians and specialists to ensure monitoring and documentation.

    There is no explicit blanket exclusion of Stelara in the policy. However, the document specifies that exceptions to remain on Stelara require prior authorization and will be reviewed on a case-by-case basis; requests to remain on the originator may be denied if not supported by case-specific documentation.

    This portion of the policy does not list any explicit exclusions. It instead focuses on clinical follow-up and documentation practices (for example, scheduling follow-ups at 30, 60 and 180 days for new ADHD medication starts) rather than naming services or indications that are categorically excluded.

    The policy does not state that remaining on originator Stelara is "not medically necessary," but it implements a plan-level preference: starting April 1, 2025 the biosimilars will be on the preferred brand tier with the lowest member cost-share, while patients who remain on Stelara will be placed on the highest-cost tier. This creates an implied non-preference through differential cost-share rather than an explicit medical necessity denial.

    There are no explicit "not medically necessary" statements

    Key Operational Thresholds and Coding-Adjacent Values

    Minimum days on medication for C&M
    Minimum days on medication (C&M)>= 210 days
    Measure population age rangeChildren ages 6-12
    ContextApplies to members with a prescription dispensed for ADHD medication who remain on therapy for the C&M phase
    C&M follow-up window length
    C&M follow-up window length270 days (9 months)
    Required additional visitsAt least two follow-up visits with any practitioner within the 270-day window
    Relation to Initiation Phase

    Provider Responsibilities, Authorizations, and Documentation

    Prior Authorization

    Prior authorization required for new starts and exceptions

    New patients starting treatment with Stelara or any of the listed biosimilars require prior authorization; requests to remain on originator Stelara instead of switching to a preferred biosimilar also require prior authorization for exception review.

    • Prior authorization is required for all new patient starts.
    • Requests to remain on Stelara (exception to switching) must be submitted for case-by-case prior authorization review.
    Billing Rule

    Use Epic for service authorizations

    Use the Epic-based Provider Portal for service authorizations; authorization numbers may be 3–4 digits and the portal or authorization letter contains the reference number and detailed status.

    Background and Rationale

    Biosimilars are described as clinically highly similar to the originator and were added to the formulary after review by the Pharmacy & Therapeutics Committee. The plan states that clinical trials demonstrated high efficacy and safety for the biosimilars and positions them as preferred options to reduce member cost-share. This rationale supports encouraging use of biosimilars as equivalent, lower-cost alternatives to the originator biologic.

    Definitions and Measure Terms

    Wezlana
    Wezlana designationInterchangeable biosimilar to Stelara
    Prescription requirementDoes not require a new prescription to the pharmacy where substitution laws allow
    Formulary placementAdded to Sanford Health Plan formulary as a preferred biosimilar
    Initiation Phase (ADD-E)
    Initiation Phase (ADD-E) follow-up expectationFollow-up visit with prescribing practitioner within 30 days after a new ADHD medication is dispensed
    Scheduling guidanceSchedule follow-up visits before refills and while patient is still in office
    Related timing suggestions

    Initial Therapy Preferences and Requirements

    Initial Therapy Preference

    Initiation guidance from the plan.

    New patient initiation: When a new patient starts treatment, providers are strongly encouraged to begin with one of the biosimilars (Selarsdi, Wezlana, Yesintek).

    Prior authorization is required for new patients; this is a plan preference to reduce member cost-share.

    Initial therapy scheduling and behavioral-first guidance

    Initial treatment instructions and behavioral-first recommendation.

    Initial ADHD/antipsychotic treatment guidance: When prescribing a new ADHD medication, schedule follow-up visits before refills: plan appointments at ~30, 60 and 180 days; consider an initial two-week supply and follow-up prescriptions for 30 days. For children/adolescents considered for antipsychotics, prioritize and document first-line psychological care (therapy/behavioral interventions) before or alongside medication when appropriate.initial two-week supply; follow-up at 30 days

    Continuation and Exception Rules

    Continuation on Originator Stelara

    Rules for patients currently on originator Stelara who wish to continue on it.

    Continuation on Stelara: Patients currently treated with Stelara may remain on Stelara only if a prior authorization exception is requested and approved based on case-specific circumstances.

    Approval is case-by-case; otherwise plan cost-share favors biosimilars and patients who remain on Stelara will be on the highest-cost tier.

    Step Therapy and Treatment Sequencing

    StepPolicy statement
    1When a new patient starts treatment, the plan strongly encourages initiation with one of the Stelara biosimilars (preferred); prior authorization is required for new patient starts.
    NotesProviders should begin conversations with patients currently on Stelara about switching to a biosimilar; prior authorization is required for new starts.
    StepPolicy statement
    1Prioritize and document first-line psychological care (therapy or behavioral interventions) for children and adolescents — especially for conditions such as ADHD, depression, and anxiety — before relying primarily on antipsychotic medications.
    NotesCollaborate with mental health professionals and educate families to support nonpharmacological treatment options and ensure access to evidence-based psychotherapy when appropriate.

    Biosimilar Formulary Placement

    Billing Rule

    Stelara — Added to formulary as preferred biosimilar; lowest cost-share starting April 1, 2025

    Selarsdi, Wezlana, and Yesintek have been added to the formulary as preferred biosimilars and will be placed on the preferred brand tier with the lowest member cost-share effective April 1, 2025.

    • Biosimilars become lowest cost-share on 2025-04-01.
    • Preferred biosimilars: Selarsdi, Wezlana, Yesintek.
    Billing Rule

    Stelara — Added to formulary as preferred biosimilar and identified as interchangeable

    Wezlana is designated an interchangeable biosimilar and, along with the other biosimilars added to the formulary, is preferred with the lowest member cost-share effective April 1, 2025; pharmacists may dispense Wezlana without requiring a new prescription where substitution laws allow.

    • Wezlana noted as interchangeable—no new prescription required for substitution when allowed.
    • Lowest cost-share for preferred biosimilars effective 2025-04-01.
    Policy Summary
    Payersanford health plan
    PolicyStelara biosimilars formulary placement and related provider guidance
    Policy CodePolicy N/A
    Change TypeFormulary additions and tiering update
    Effective DateApr 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for new patients starting Stelara or biosimilars and document case-specific justification for exceptions to remain on originator Stelara.
    SourceLink
    On This Page
    Coverage Criteria and Policy RulesKey Operational Thresholds and Coding-Adjacent ValuesProvider Responsibilities, Authorizations, and DocumentationBackground and RationaleDefinitions and Measure TermsInitial Therapy Preferences and RequirementsContinuation and Exception RulesStep Therapy and Treatment SequencingBiosimilar Formulary Placement
    Window measured after the 30-day Initiation Phase ends
    Initiation Phase follow-up timing
    Initiation Phase follow-up timingOne follow-up visit within 30 days of medication start
    Target populationChildren ages 6-12 with a new ADHD medication dispensed
    PurposeEnsure timely management and adjustment of ADHD treatment per ADD-E measure
    • Access the Provider Portal to view authorization details and status.
    • Refer to the authorization number on the letter or in the portal (may be 3–4 digits).
    • Open the specific authorization to view full status because the main summary page may not show current status.
    Step Therapy

    Preferred initiation on biosimilars

    When initiating therapy for a new patient, providers are strongly encouraged to start with one of the preferred biosimilars; prior authorization is still required for new patient starts.

    • Begin new patients on a biosimilar (Selarsdi, Wezlana, Yesintek) per plan preference.
    • Submit a prior authorization for any new start.
    Note

    First-line psychological care expectation

    For children/adolescents considered for antipsychotic therapy, prioritize and document first-line psychological care (therapy or behavioral interventions) before or alongside prescribing antipsychotics.

    • Document the use of psychotherapy or behavioral interventions as first-line care when appropriate.
    • Coordinate and record behavioral treatment prior to relying primarily on antipsychotic medication.
    Documentation Required

    Concurrent review submission steps

    To submit a concurrent review on an active authorization, locate the authorization in the portal, open it, use the add note/attachment function to add a summary and supporting medical documentation, then add the note to send the request to utilization management for review.

    • Patient List > Authorization by Member to locate active authorization.
    • Open the authorization and click add note/attachment (top left).
    • Add request/notes in the free-form section, include a summary, attach supporting medical documentation, then click add note to submit.
    Documentation Required

    Visit scheduling and visit type documentation

    Document scheduling and completion of follow-up visits at approximately 30, 60 and 180 days from the initial visit; note that only one visit between days 31 and 300 may be an e-visit or virtual check-in.

    • Schedule follow-up visits while the patient is still in the office and document their dates.
    • Prescribe an initial two-week supply and follow-up prescriptions for 30 days to ensure return.
    • If an e-visit is used, ensure no more than one e-visit occurs between days 31 and 300 and document it.
    Denial Risk

    Prior authorization for exceptions to switching

    Requests to remain on originator Stelara instead of switching to a preferred biosimilar require prior authorization and may be denied if case-specific clinical justification is not provided.

    • Submit an exception prior authorization with case-specific documentation to justify staying on Stelara.
    • Without adequate justification, exception requests to remain on Stelara may be denied.
    Denial Risk

    Follow-up timing noncompliance

    Failure to schedule and document the required follow-up visits at the specified intervals (initiation within 30 days and continuation visits within the continuation window) risks not meeting measure expectations and may affect authorization/coverage performance.

    • Ensure the initiation follow-up occurs within 30 days of starting medication.
    • Ensure additional continuation follow-ups occur per plan guidance (e.g., 60 and 180 days) and document them.
    Consider visits at 30, 60, and 180 days per planning guidance
    Continuation and Maintenance (C&M) Phase
    C&M Phase core criteriaMember remained on ADHD medication for >= 210 days
    Additional visit requirementAt least two additional follow-up visits with any practitioner within 270 days after the Initiation Phase ended
    E-visit allowanceOne e-visit allowed between days 31 and 300 (documentation recommended)
    APP measure
    APP measure expectationChildren/adolescents prescribed antipsychotics should receive first-line psychological care (therapy/behavioral interventions) when appropriate
    DocumentationPrioritize and document psychological care before or alongside antipsychotic prescribing
    GoalReduce over-reliance on medication and support appropriate use of antipsychotics
    APM measure
    APM monitoring requirementsRegular metabolic monitoring for children/adolescents on antipsychotics (weight/height, blood pressure, glucose, lipids)
    RationaleAntipsychotics can cause weight gain, hyperglycemia, and lipid abnormalities that increase long-term health risks
    Care coordinationUse EHR reminders and coordinate with other clinicians to ensure routine metabolic screenings

    Only one visit between days 31 and 300 may be an e-visit or virtual check-in; arrange follow-ups while patient is still in office where possible.

    Billing Rule

    Stelara — Added to formulary as preferred biosimilar; lowest cost-share starting April 1, 2025

    Selarsdi and Yesintek (the listed biosimilars) are added as preferred formulary options and will carry the lowest member cost-share beginning April 1, 2025.

    • Preferred biosimilars: Selarsdi, Yesintek.
    • Effective date for lowest cost-share: April 1, 2025.